Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From Insud Pharma

Asia Deal Watch: Lupin Signs Up Three EU Marketing Partners For NaMuscla

Lupin links with Exeltis, Cresco and Macure to sell the NDM therapy in western and central Europe. Plus deals involving Cipla, GoApptiv, Takeda, Debiopharm, PharmaMar and TTY.

Deals Business Strategies

EU Injunction Compensation Is Not Automatic

Generics firms barred from European markets by injunctions granted on patents that are subsequently found to be invalid are not automatically entitled to damages from the originator, the CJEU has ruled in a Hungarian case involving Gedeon Richter, Exeltis and Bayer.

Intellectual Property Legal Issues

Last Year’s Winners Build On Successes

Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.

Generic Drugs Biosimilars

Alvogen Expands In CEE With Exeltis Portfolio

Alvogen has struck a deal with Insud’s Exeltis to gain rights to 23 women’s healthcare brands in Russia, Ukraine and Kazakhstan.

Deals Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Vaccines
  • Other Names / Subsidiaries
    • Althea S.A
    • Altian Pharma
    • BC Pharma
    • Chemway
    • Effik
    • Exeltis Healthcare S.L
    • Grupo JUSTE
    • Justesa Imagen
    • Juste Farma
    • Sinensix
    • Insud Pharma
    • CHEMO Group
UsernamePublicRestriction

Register